This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Brian Vastag

JAMA. 2001;286:1163-1164.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—After word of President George W. Bush's decision to allow federal funding for established embryonic stem cells leaked to the media early last month, one surprise was still left: at least 60 of the cell lines exist, Bush said on August 9. But less than a dozen had been announced, leading top researchers to question the newfound cells' viability and even their existence.

It turns out that behind the scenes, Lana Skirboll, PhD, director of science policy at the National Institutes of Health (NIH), was canvassing the world. "We looked far and wide," she said at a news conference the day after the president's announcement. Most of the newly disclosed lines originated at private companies, all of which were apparently better at keeping secrets than Bush's staff.

Six types of cells derived from undifferentiated embryonic stem cells—liver, heart muscle, nerve, pancreatic islet, bone, and blood cells—are included . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?